Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Seoul National University Hospital
With
H. Lundbeck A/S
* Study institutions: Four university hospitals in Korea
* Design: Multi-center, randomized, placebo-controlled, double-blind clinical trial
* Subjects: 74 probable Alzheimer's disease patients who have been taking donepezil at stable dose within 2 months (Escitalopram 37 : Placebo 37)
Age
40–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age:40\~90 years
Education:not illiterate
Clinical Dementia Rating (CDR):0.5\~2
Modified Hachinski Ischemic Score (Rosen et al., 1979):less than 4
Dementia according to DSM-IV criteria
Probable Alzheimer's disease according to NINCDS-ADRDA criteria
Current ongoing donepezil medication at stable doses (5 \~ 10 mg/day) for at least 2 months
You may not be if
Evidence of delirium, confusion or altered consciousness
Evidence of Parkinson's disease, stroke, brain tumor and normal pressure hydrocephalus
Evidence of infectious or inflammatory brain disease
Evidence of serious cerebrovascular diseases
Current major depressive disorder or other major psychiatric illnesses
Evidence of serious or unstable medical illnesses which can significantly change cognitive state
History of alcohol or other substance dependence
Any antidepressant medications within the previous 4 weeks
Absence of a reliable and cooperative collateral informant
Any conditions which prohibit MRI scan, such as presence of pacemaker or cerebrovascular clip, and claustrophobia
Evidence of focal brain lesions on MRI including lacunes and white matter hyperintensity lesions of grade 2 or more by Fazeka scale
